0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          BACKGROUND. In type 1 diabetes (T1D), adjuvant treatment with inhibitors of the renin-angiotensin-aldosterone system (RAAS), which dilate the efferent arteriole, is associated with prevention of progressive albuminuria and renal dysfunction. Uncertainty still exists as to why some individuals with long-standing T1D develop diabetic kidney disease (DKD) while others do not (DKD resistors). We hypothesized that those with DKD would be distinguished from DKD resistors by the presence of RAAS activation.

          METHODS. Renal and systemic hemodynamic function was measured before and after exogenous RAAS stimulation by intravenous infusion of angiotensin II (ANGII) in 75 patients with prolonged T1D durations and in equal numbers of nondiabetic controls. The primary outcome was change in renal vascular resistance (RVR) in response to RAAS stimulation, a measure of endogenous RAAS activation.

          RESULTS. Those with DKD had less change in RVR following exogenous RAAS stimulation compared with DKD resistors or controls (19%, 29%, 31%, P = 0.008, DKD vs. DKD resistors), reflecting exaggerated endogenous renal RAAS activation. All T1D participants had similar changes in renal efferent arteroilar resistance (9% vs. 13%, P = 0.37) irrespective of DKD status, which reflected less change versus controls (20%, P = 0.03). In contrast, those with DKD exhibited comparatively less change in afferent arteriolar vascular resistance compared with DKD resistors or controls (33%, 48%, 48%, P = 0.031, DKD vs. DKD resistors), indicating higher endogenous RAAS activity.

          CONCLUSION. In long-standing T1D, the intrarenal RAAS is exaggerated in DKD, which unexpectedly predominates at the afferent rather than the efferent arteriole, stimulating vasoconstriction.

          FUNDING. JDRF operating grant 17-2013-312.

          Abstract

          In long-standing T1D patients, the intrarenal RAAS is exaggerated in diabetic nephropathy, which unexpectedly predominates at the afferent rather than the efferent arteriole, stimulating vasoconstriction.

          Related collections

          Author and article information

          Contributors
          Journal
          JCI Insight
          JCI Insight
          JCI Insight
          JCI Insight
          American Society for Clinical Investigation
          2379-3708
          11 January 2018
          11 January 2018
          11 January 2018
          : 3
          : 1
          : e96968
          Affiliations
          [1 ]Division of Endocrinology and Metabolism and
          [2 ]Division of Nephrology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
          [3 ]Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
          [4 ]Research Division, Barbara Davis Center for Diabetes, Aurora, Colorado, USA.
          [5 ]Research Division, Joslin Diabetes Center, Boston, Massachusetts, USA.
          [6 ]Department of Ophthalmology and Vision Sciences, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
          [7 ]Joint Department of Medical Imaging, Division of Cardiothoracic Radiology, University Health Network, Toronto, Ontario, Canada.
          [8 ]Ellen and Martin Prosserman Centre for Neuromuscular Diseases, Krembil Neuroscience Centre, Division of Neurology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada.
          Author notes
          Address correspondence to: Julie A. Lovshin, Room H154, H-Wing, 2075 Bayview Avenue, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada, M4N 3M5. Phone: 416.480.4800 ext. 2264; Email: julie.lovshin@ 123456sunnybrook.ca .

          Authorship note: B.A. Perkins and D.Z.I. Cherney are co–senior authors.

          Author information
          http://orcid.org/0000-0001-5282-4034
          http://orcid.org/0000-0002-5805-4883
          Article
          PMC5821172 PMC5821172 5821172 96968
          10.1172/jci.insight.96968
          5821172
          29321380
          9348801c-1c02-4fa7-b2fb-24947cc6a199
          Copyright © 2018, American Society for Clinical Investigation
          History
          : 23 August 2017
          : 28 November 2017
          Funding
          Funded by: Juvenile Diabetes Research Foundation
          Award ID: JDRF Operating Grant No. 17-2013-312
          Categories
          Clinical Medicine

          Endocrinology,Nephrology,Diabetes
          Endocrinology, Nephrology, Diabetes

          Comments

          Comment on this article